MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside
Stock Soars on Catalyst News MindMed’s stock has skyrocketed in recent weeks. After languishing in the single digits, MNMD climbed above $12 in late September and spiked to $13.09 on Oct. 14, its highest level in over a year ts2.tech marketbeat.com. The surge has pushed the stock roughly +68% year-to-date ts2.tech. Heavy trading volume accompanied the rise, as investors reacted to the latest clinical and regulatory news. (By Oct 17, shares were trading around $13.60 stockinvest.us.) This rally has made MindMed one of the year’s best-performing small-cap biotechs. Wall Street sentiment is strongly positive: MarketBeat notes MNMD has seven analyst